Bradley Merrill Thompson, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in HealthData Management, in “FDA Seeks $46M to Fund National Evaluation System for Health Technology,” by Greg Slabodkin.
Following is an excerpt:
However, Bradley Merrill Thompson, an attorney at Washington, D.C.-based law firm Epstein Becker Green who counsels medical device companies on regulatory issues, believes this is a tough political climate for the FDA to raise as much money as they are requesting for NEST.
He’s skeptical that Congress will “cough up” the millions of dollars in additional funding the agency says it needs for the system.
“They try to sell this on the basis of being able to bring products to market quicker if they have a better safety net,” observes Thompson. “I’m not sure how many people are actually buying into that promotional claim by FDA.”